Rockefeller Capital Management L.P. Raises Stock Position in Boston Scientific Corporation $BSX

Rockefeller Capital Management L.P. raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 70.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 595,938 shares of the medical equipment provider’s stock after purchasing an additional 247,097 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Boston Scientific were worth $56,823,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the stock. FWL Investment Management LLC acquired a new stake in Boston Scientific during the second quarter worth about $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific in the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Colonial Trust Co SC increased its holdings in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank lifted its stake in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the transaction, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Jefferies Financial Group cut their price target on Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Piper Sandler reiterated an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a research report on Friday, June 12th. Stifel Nicolaus set a $75.00 price objective on Boston Scientific in a research report on Wednesday, May 27th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $55.00 target price (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.08.

Boston Scientific Stock Performance

NYSE BSX opened at $45.30 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock’s 50 day simple moving average is $54.71 and its 200-day simple moving average is $73.03. The company has a market cap of $67.33 billion, a PE ratio of 18.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56. Boston Scientific Corporation has a 1-year low of $44.44 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the prior year, the company earned $0.75 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.